Letter to Shareholders From Imagenetix, Inc. President/CEO Willi...( SAN DIEGO Aug. 26 /...),Health

SAN DIEGO, Aug. 26 /PRNewswire-FirstCall/ -- Imagenetix, Inc. (OTC Bulletin Board: IAGX) today issued the following letter to all shareholders.

To all shareholders and supporters of Imagenetix, Inc.: the purpose of this letter is to update you on activities at the company. It is my intention to provide periodic communication to our shareholders through these letters as a means to provide insight to you on topical issues and to provide a uniform status report on activities at the company.

I am delighted to share with you that fiscal 2009, the twelve months ended March 31, 2009, was a pivotal year for your company. First, we enjoyed continued scientific achievements; second, we expanded the distribution of our flag-ship branded product, InflameAway Celadrin(R); and, third, as we enter the new fiscal year, we will be introducing a new innovative product, BioGuard(TM). In addition, we continue to position our fat loss product.

Scientific Achievements

The results of a second study conducted on our proprietary compound, 1-TDC, for the treatment of periodontal disease has been published in the July issue of The Journal of Periodontology and is also available online at: http://www.joponline.org/loi/jop (J Periodontal 2009; 80(7):1103-13).

In the recent study, 1-TDC was applied to the gum line using the rabbit periodontitis model developed by Boston University investigators. The study results show that 1-TDC stopped the progression of periodontal disease with a significant improvement and restoration in tissue and bone health compared to the placebo group.

We now have two published animal studies showing clear evidence of efficacy and we continue to position our 1-TDC for a phase 1 trial with the FDA. In
'/>"/>